WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

Efavirenz/Lamivudine/Tenofovir disoproxil fumarate 600 mg/300 mg/300 mg Tablets*

International Nonproprietary Names (INN):
Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets

Abstract

Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets, manufactured at Macleods Pharmaceuticals Limited, Baddi, Dist. Solan, India was included in the WHO list of prequalified medicinal products for the treatment of HIV/AIDS on 04 June 2015.

Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets, is indicated for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in adults and adolescents from 10 years of age and weighing at least 35 kg.

The active pharmaceutical ingredients(APIs) efavirenz, lamivudine and tenofovir disoproxil fumarate are the non-nucleoside reverse transcriptase inhibitor efavirenz, the nucleoside reverse transcriptase inhibitor lamivudine and the nucleotide reverse transcriptase inhibitor tenofovir disoproxil fumarate.
The APIs, as separate formulations, have been investigated in combination therapy in several clinical trials, in both treatment-naïve and treatment-experienced patients.

The most frequent adverse events observed during treatment with efavirenz, lamivudine and tenofovir disoproxil fumarate were rash, diarrhoea, nausea, vomiting, dizziness, asthenia, and hypophosphataemia.

The most serious safety concerns with efavirenz, lamivudine and tenofovir disoproxil fumarate are related to the kidneys (e.g. renal impairment, renal failure and proximal renal tubulopathy), the psyche (e.g. suicide and neurosis) the liver (e.g. acute hepatitis, hepatic failure and hepatic steatosis), the skin (e.g. Stevens-Johnson syndrome), and the muscles and bones (e.g. rhabdomyolysis and osteomalacia). Discontinuation of therapy with Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets, in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.

The efficacy and safety profile of efavirenz, lamivudine and tenofovir disoproxil fumarate is well established based on extensive clinical experience in the treatment of HIV infection.

On the basis of data submitted and public information on the use of combination therapy in HIV/AIDS, the team of assessors advised that Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets, is of acceptable quality, efficacy and safety to allow the inclusion of Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets , in the list of prequalified medicinal products.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

Summary of Prequalification Status for Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate 600 mg/300 mg/300 mg Tablets:

	Initial Acceptance					
	Date	**Outcome**	**Date**	**Outcome**	**Date**	**Outcome**
Status on PQ list, i.e. date of listing	04 June 2015	listed				
Dossier Evaluation (Quality assurance)						
Quality	08 May 2015	MR				
Bioequivalence	21 May 2015	MR				
Safety, Efficacy	NA	NA				
Inspection Status						
GMP(re-)inspection						
API	16 April 2014	MR				
API	29 May 2014	MR				
API	28 Aug 2014	MR				
FPP	17 July 2014	MR				
GLP (re-)inspection	NA	NA				
GCP (re-)inspection	NA	NA				

MR: meets requirements
NA: not applicable, not available